Please assess the completion status of the following clinical trial:

Trial Title: ASpirin vs Triflusal for Event Reduction In Atherothrombosis Secondary Prevention (ASTERIAS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a stable coronary artery disease (CAD)~* Patients with a history of non-cardioembolic ischemic stroke.~Exclusion Criteria:~* Hypersensitivity reaction or contraindication to triflusal or aspirin~* Active bleeding or history of severe bleeding (peptic ulcer, trauma or intracranial hemorrhage)~* Blood coagulation disorders~* Uncontrolled severe hypertension~* Pregnancy or breastfeeding~* Liver disease (alanine or aspartate aminotransferase more than 3 times the upper normal limit)~* Malignancy that may potentially increase the risk of hemorrhage~* Drug or alcohol abuse~* HIV infection~* Chronic disorders requiring long-term treatment with systemic nonsteroidal anti-inflammatory drugs (NSAIDs).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aspirin (Type: ACTIVE_COMPARATOR): 100mg/day
- Triflusal (Type: ACTIVE_COMPARATOR): 300mg twice or 600mg once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).